<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2586">
  <stage>Registered</stage>
  <submitdate>24/11/2009</submitdate>
  <approvaldate>24/11/2009</approvaldate>
  <nctid>NCT01019421</nctid>
  <trial_identification>
    <studytitle>Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease</studytitle>
    <scientifictitle>Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EudraCT 2009-011845-24</secondaryid>
    <secondaryid>12936A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lu AE58054
Treatment: drugs - Placebo

Experimental: Lu AE58054 - 

Placebo Comparator: Placebo - 


Treatment: drugs: Lu AE58054
Add-on treatment to donepezil

Treatment: drugs: Placebo
Add-on treatment to donepezil

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in cognition after 24 weeks</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in global function, activities of daily living, safety and tolerability, pharmacokinetics/pharmacodynamics</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  The patient (or if applicable the legally acceptable representative (LAR) and if
             different from the responsible caregiver) and the responsible caregiver are able to
             read and understand the Informed Consent Form.

          -  The patient has a knowledgeable and reliable caregiver who will accompany the patient
             to all clinic visits during the study.

          -  The patient (or if applicable the LAR and if different from the responsible caregiver)
             and the responsible caregiver have signed the Informed Consent Form.

          -  The patient has probable AD consistent with NINCDS-ADRDA criteria.

          -  The patient is a man or woman, aged at least 50 years.

          -  The patient has been treated with donepezil on a stable dose for at least 3 months
             prior to screening.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  The patient has evidence of any clinically significant neurodegenerative disease or
             other serious neurological disorders other than AD including but not limited to Lewy
             body dementia, fronto-temporal dementia, Parkinson's disease, Huntington's disease,
             major cortical stroke, major head trauma and, primary or secondary cerebral neoplasia.

          -  The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
             Text Revision (DSM-IV-TR) Axis I disorder other than AD including amnestic disorders,
             major depressive disorder, delirium, schizophrenia or schizoaffective disorder,
             bipolar disorder, psychosis, panic, post traumatic stress disorder or/and cognitive
             disorder not otherwise specified.

          -  The patient has clinical and radiological findings that fulfil the standards of the
             National Institute of Neurological Disorders and Stroke and Association Internationale
             pour la Recherch√© et l'Enseignement en Neurosciences (NINDS-AIREN) criteria for
             vascular dementia.

          -  The patient has CT or MRI evidence of hydrocephalus, stroke, a space-occupying lesion,
             cerebral infection or any clinically significant central nervous system disease other
             than AD.

          -  The patient has clinically significant abnormal vital signs.

          -  The patient has one or more laboratory values outside the normal range, based on the
             blood or urine samples, which are, in the investigator's judgement, considered to be
             clinically significant.

          -  The patient has a clinically significant abnormal ECG.

          -  The patient has an oncological diagnosis (haematological or solid tumour) that is
             currently being treated, or for which there has been treatment within 5 years
             preceding screening, or for which there is still evidence of active disease (patients
             with local dermatological tumours such as basal or squamous cell carcinoma may be
             included).

          -  The patient's donepezil therapy is likely to be interrupted or discontinued during the
             study.

          -  The patient has a disease or takes medication that, in the investigator's judgement,
             could interfere with the assessments of safety, tolerability, or efficacy.

          -  The patient is, in the investigator's judgement, unlikely to comply with the clinical
             study protocol or is unsuitable for any reason.

          -  The patient is a member of the site personnel or their immediate families.

          -  The patient is treated against his/her will (for example, by court order).

          -  The patient or patient caregiver is unwilling or unable to abide by the visit schedule
             and other requirements of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>278</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>AU004 - East Gosford</hospital>
    <hospital>AU002 - Heidelberg West</hospital>
    <hospital>AU005 - Kew</hospital>
    <hospital>AU001 - Nedlands</hospital>
    <hospital>AU003 - Woodville South</hospital>
    <postcode> - East Gosford</postcode>
    <postcode>3081 - Heidelberg West</postcode>
    <postcode>3101 - Kew</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>5011 - Woodville South</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Burlington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Gatineau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Kamloops</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Kingston</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Penticton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Sherbrooke</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kladno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kutna Hora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Litomerice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Rychnov nad Kneznou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ellwangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erbach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gunzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Unterhaching</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lamezia Terme</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sopot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Elche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Majadahonda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Terrassa</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>H. Lundbeck A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to accept or reject the hypothesis that Lu AE58054 improves
      cognition and functional outcomes in patients with moderate Alzheimer's Disease, already in
      treatment with donepezil.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01019421</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Email contact via H. Lundbeck A/S</name>
      <address>LundbeckClinicalTrials@lundbeck.com</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>